Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.

Acta neuropathologica communications - 22 Aug 2018

Vitale Francesca, Giliberto Luca, Ruiz Santiago, Steslow Kristen, Marambaud Philippe, d'Abramo Cristina

Abstract excerpt

Tau, the main component of the neurofibrillary tangles (NFTs), is an attractive target for immunotherapy in Alzheimer's disease (AD) and other tauopathies. MC1/Alz50 are currently the only antibodies targeting a disease-specific conformational modification of tau. Passive immunization experiments using intra-peritoneal injections have previously shown that MC1 is effective at reducing tau pathology in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Antigen-Antibody Complex

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Astrocytes

Share to Dependovirus

Share to Immunoglobulin Heavy Chains

Share to Immunoglobulin Light Chains

Share to tau Proteins

Share to Tauopathies

Source

Open in PubMed Open full text

Identifiers

PMID: 30134961
DOI: 10.1186/s40478-018-0585-2
PMCID: PMC6103963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.PMID 30134961Read ↗

AAV-mediated peripheral single chain variable fragments’ administration to reduce cerebral tau in adult P301S transgenic mice: mono- vs combination therapySemantic proximity Read ↗

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative PhenotypesSemantic proximity Read ↗

Anti-Tau VHH Therapy Against PHF6: A Safe Approach to Slowing the Phenotype of Tau PathologySemantic proximity Read ↗

Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology.Semantic proximity Read ↗

Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.Semantic proximity Read ↗

Virally encoded single-chain antibody fragments targeting alpha-synuclein protect against motor impairments and neuropathology in a mouse model of synucleinopathySemantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Targeting intracellular tau with a gene-encoded single-chain antibody promotes neuronal homeostasis and ameliorates tau pathologySemantic proximity Read ↗

Inhibition of tau neuronal internalization using anti-tau single domain antibodiesSemantic proximity Read ↗

Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.Semantic proximity Read ↗

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy ModelsSemantic proximity Read ↗

Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.